ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016
Identification of novel biomarkers associated with poor patient outcomes in invasive breast carcinoma.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- The role of PPM1D in cancer and advances in studies of its inhibitors.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020Pooled it
- Activation of TP53 target genes in the primary response of triple-negative breast cancer cells to doxorubicin treatment.Scientific reports · 2025Article
- Emerging roles of prohibitins in cancer: an update.Cancer gene therapy · 2025Review
- Integration of scHi-C and scRNA-seq data defines distinct 3D-regulated and biological-context dependent cell subpopulations.Nature communications · 2024Article
- Article
- Prognostic value of Maspin protein level in patients with triple negative breast cancer.Scientific reports · 2024Article
- UBXN1 promotes liver tumorigenesis by regulating mitochondrial homeostasis.Journal of translational medicine · 2024Article
- Androgens Modulate Bcl-2 Agonist of Cell Death (BAD) Expression and Function in Breast Cancer Cells.International journal of molecular sciences · 2023Article
- Prognostic value of integrin αV expression and localization pattern in invasive breast carcinomas.Neoplasia (New York, N.Y.) · 2022Article
- GTSE1 is possibly involved in the DNA damage repair and cisplatin resistance in osteosarcoma.Journal of orthopaedic surgery and research · 2021Article
- Wip1 controls the translocation of the chromosomal passenger complex to the central spindle for faithful mitotic exit.Cellular and molecular life sciences : CMLS · 2021Article
- Sensitivity to differential NRF1 gene signatures contributes to breast cancer disparities.Journal of cancer research and clinical oncology · 2020Article
- Caffeic Acid Versus Caffeic Acid Phenethyl Ester in the Treatment of Breast Cancer MCF-7 Cells: Migration Rate Inhibition.Integrative cancer therapies · 2018Article
- High G2 and S-phase expressed 1 expression promotes acral melanoma progression and correlates with poor clinical prognosis.Cancer science · 2018Article
- Significance of prohibitin domain family in tumorigenesis and its implication in cancer diagnosis and treatment.Cell death & disease · 2018Review
- Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt/PHB interaction to activate the GADD45α pathway.Journal of experimental & clinical cancer research : CR · 2018Article
- Tissue Expression of Prohibition-I and It's Relationship With Prognostic Factors in Breast Cancer.Iranian journal of pathology · 2018Article
- The role of DNA methylation in human trophoblast differentiation.Epigenetics · 2018Article
- Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.Oncology letters · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast carcinoma (BC) corresponds to 23 % of all cancers in women, with 1.38 million new cases and 460,000 deaths worldwide annually. Despite the significant advances in the identification of molecular markers and different modalities of treatment for primary BC, the ability to predict its metastatic behavior is still limited. The purpose of this study was to identify novel molecular markers associated with distinct clinical outcomes in a Brazilian cohort of BC patients. We generated global gene expression profiles using tumor samples from 24 patients with invasive ductal BC who were followed for at least 5 years, including a group of 15 patients with favorable outcomes and another with nine patients who developed metastasis. We identified a set of 58 differentially expressed genes (p ≤ 0.01) between the two groups. The prognostic value of this metastasis signature was corroborated by its ability to stratify independent BC patient datasets according to disease-free survival and overall survival. The upregulation of B3GNT7, PPM1D, TNKS2, PHB, and GTSE1 in patients with poor outcomes was confirmed by quantitative reverse transcription polymerase chain reaction (RT-qPCR) in an independent sample of patients with BC (47 with good outcomes and eight that presented metastasis). The expression of BCL2-associated agonist of cell death (BAD) protein was determined in 1276 BC tissue samples by immunohistochemistry and was consistent with the reduced BAD mRNA expression levels in metastatic cases, as observed in the oligoarray data. These findings point to novel prognostic markers that can distinguish breast carcinomas with metastatic potential from those with favorable outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.